Novo Nordisk shares fall 20% after company names new CEO and lowers its financial outlook
In a statement on Tuesday, Novo Nordisk said it expects its sales for 2025 to grow 8%-14%, down from projections of 13%-21% in May. It also lowered its expectations for operating profit growth to 10%-16%, down from 16%-24% in May.
The updated outlook "reflects the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition," the company said. Glucagon-like peptide-1 agonists (GLP-1s), a class of drugs used to manage diabetes, have upended the weight-loss industry.
The Danish pharmaceutical company also announced on Tuesday the appointment of Maziar Mike Doustdar as president and CEO. Doustdar, who has worked at Novo Nordisk for over 30 years, will take the helm starting on Aug. 7.
Doustdar will succeed Lars Fruergaard Jorgensen, who announced his departure as CEO of Novo Nordisk in May, following a steep decline in the company's share price, which has dropped nearly 37% since the start of this year.
Reached for comment, a Novo Nordisk spokesperson said they did not have anything additional to share before the company's earnings call, which is scheduled for Wednesday, Aug. 6.
While global sales of Wegovy are growing, sales of the weight-loss drug are expected to weaken in certain markets due to increased competition from compounded versions of the drug.
Compounded weight-loss drugs have the same active ingredients as Wegovy and other popular brands such as Ozempic, and are used as substitutes when the name-brand drugs aren't available. However, the Food and Drug Administration (FDA) in April said there is no longer a shortage of GLP-1s and ordered compounding pharmacies to stop selling their copycat versions of the popular weight-loss drugs.
Despite efforts to stymie them, however, compounded versions of the drugs continue to penetrate the market, giving consumers a cheaper option to name-brands like Wegovy, which can cost more than $1000 per package for those without insurance.
In June, Novo Nordisk ended its partnership with Hims & Hers Health over claims that the online drug retailer was selling fake versions of Wegovy, a move Novo Nordisk said "put patient safety at risk."
CBS News medical contributor Dr. Céline Gounder told CBS News last year that there is not a lot of oversight over the compounded drug market, and that there is a wide range when it comes to the quality and risk associated with each drug.
Novo Nordisk said it is pursuing multiple avenues to "protect patients from knockoff 'semaglutide' drugs" including litigation. Semaglutide is the active ingredient found in Wegovy and Ozempic.
"Novo Nordisk is deeply concerned that, without aggressive intervention by federal and state regulators and law enforcement, patients will continue to be exposed to the significant risks posed by knockoff 'semaglutide' drugs made with illicit or inauthentic foreign active pharmaceutical ingredients," the company said in its statement.The Associated Press
contributed to this report.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Sandoz to offer generic weight-loss drugs in Canada at up to 70% discount, FT reports
(Reuters) -Swiss generic drug manufacturer Sandoz plans to launch unbranded weight-loss drugs in Canada at discounts of up to 70% compared to branded versions once patents begin to expire next year, CEO Richard Saynor told the Financial Times. Sandoz is yet to finalise the pricing for its generic weight-loss and diabetes drug semaglutide, but a price cut of "60 or 70 per cent of the list price" was achievable, Saynor told the newspaper. Prices could drop further as more generic versions become available, Saynor said, noting, "If you were selling this at $40 or $50 a month, the market could be two or three times bigger in terms of the number of patients." Branded weight-loss and diabetes medications, such as Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro and Zepbound, are currently priced between $200 and $400 for a one-month supply, according to the FT report. Novo Nordisk's medications use semaglutide as the active ingredient, while Eli Lilly's medications use tirzepatide. Sandoz did not immediately respond to a Reuters request for comment. The move comes as demand for weight-loss and diabetes drugs has surged globally, driven by their effectiveness in managing obesity and diabetes. Last month, a top Biocon executive told Reuters that the biopharmaceutical company aims to launch generic copies of the blockbuster weight-loss drug Wegovy in Canada within the next two years. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Boston Globe
10 hours ago
- Boston Globe
Vertex next-generation pain candidate fails Phase 2 trial
'We do not plan to advance VX-993 as monotherapy in acute pain, because we do not expect that it will be superior to our [existing] NaV1.8 inhibitors,' said CEO Reshma Kewalramani during a Monday afternoon earnings call with investors, using a scientific shorthand for the class of drugs. She noted that the company will continue a trial testing the drug in patients with diabetes who have chronic nerve pain. It was one of multiple setbacks the company disclosed for its pain franchise Monday, as it announced its second-quarter earnings. Advertisement Vertex also announced that longtime chief scientist David Altshuler was retiring next year, to be replaced by head of global research Mark Bunnage. Altshuler, an accomplished academic geneticist, took the post in 2015 and presided over the launch of its most important Advertisement Although Journavx was On Monday, though, the company disclosed that the the Food and Drug Administration 'indicated they do not see a path' for Vertex to obtain a broad approval for Journavx in 'peripheral neuropathic pain' — i.e., chronic pain caused by nerve damage or dysfunction. Instead the company will have to obtain approval in individual subsets of chronic pain. Accordingly, Vertex said it will cancel a planned Phase 3 trial in lumbosacral radiculopathy, also known as sciatica, which the company said affects about 4 million people. Journavx had already failed to outperform placebo in a Phase 2 sciatica trial. Instead it will launch a second Phase 3 trial in diabetic peripheral neuropathy, which affects about 2 million people, in the hope of first getting approval in that indication. At the same time, Vertex announced better-than-expected sales for Journavx in acute pain, with more than 110,000 prescriptions filled. Although the pill was hailed as a potential public health breakthrough for providing a non-addictive alternative to opioids, analysts questioned how widely they would be prescribed, given the availability of cheap alternatives. On Monday, Vertex said it earned $12 million from Journavx, compared to consensus Wall Street projections of $6.7 million. Advertisement Vertex also said it has now treated 29 patients with Casgevy, its gene editing therapy for sickle cell disease, including 16 in the last quarter. Casgevy, which has been slow to launch, earned $30.4 million from second-quarter sales.
CNBC
12 hours ago
- CNBC
Hims & Hers stock falls 10% on revenue miss
Shares of Hims & Hers Health fell 9% in extended trading on Monday after the telehealth company reported second-quarter results that missed Wall Street's expectations for revenue. Here's how the company did based on average analysts' estimates compiled by LSEG: Revenue at Hims & Hers increased 73% in the second quarter from $315.6 million during the same period last year, according to a release. Hims & Hers reported a net income of $42.5 million, or 17 cents per share, compared to $13.3 million, or 6 cents per share, during the same period a year earlier. For its third quarter, Hims & Hers said it expected to report revenue between $570 million to $590 million, while analysts were expecting $583 million. The company said its adjusted EBITDA for the quarter will be between the range of $60 million to $70 million. Analysts polled by StreetAccount were expecting $77.1 million. Hims & Hers has faced controversy in recent months over its continued sale of compounded GLP-1s, which are cheaper, unapproved versions of the blockbuster diabetes and weight loss drugs. Compounded drugs can be mass produced when brand-name treatments are in shortage, but the U.S. Food and Drug Administration announced in February that ongoing supply issues had been resolved. Some telehealth companies, including Hims & Hers, have continued to offer the compounded medications. It's legal for patients to access personalized doses of the knockoffs in unique cases, like if they are allergic to an ingredient in a branded product, for instance. Hims & Hers has said consumers may still be able to access personalized doses through its site if clinically applicable. In June, Hims & Hers shares tumbled more than 30% after a short-lived collaboration with Novo Nordisk fell apart. The drugmaker said Hims & Hers "failed to adhere to the law which prohibits mass sales of compounded drugs" under the "false guise" of personalization. Hims & Hers reported adjusted EBITDA of $82 million for its second quarter, up from $39.3 million last year and above the $73 million expected by StreetAccount. Hims & Hers will host its quarterly call with investors at 5 p.m. ET.
